Cediranib: all 93 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerRecruitingNCT04090567Phase 2
• WIRE - Novel Treatments in Renal Cell CancerRecruitingNCT03741426Phase 2
• Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsActive, not recruitingNCT04739800Phase 2Results posted
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingNCT03660826Phase 2Results posted
• Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingNCT03334617Phase 2Results posted
• Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-OlaparibCompletedNCT03314740Phase 2Results posted
• Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingNCT02974621Phase 2Results posted
• Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung CancerTerminatedNCT02899728Phase 2Results posted
• Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate CancerActive, not recruitingNCT02893917Phase 2Results posted
• Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian CancerCompletedNCT02889900Phase 2Results posted
• Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerActive, not recruitingNCT02502266Phase 2/3Results posted
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsActive, not recruitingNCT02498613Phase 2Results posted
• Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02446600Phase 3Results posted
• Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerActive, not recruitingNCT02345265Phase 2Results posted
• Sunitinib or Cediranib for Alveolar Soft Part SarcomaCompletedNCT01391962Phase 2Results posted
• Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary CancersTerminatedNCT01229111Phase 2Results posted
• Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01132820Phase 2Results posted
• Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast CancerActive, not recruitingNCT01116648Phase 1/2Results posted
• Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural MesotheliomaActive, not recruitingNCT01064648Phase 1/2Results posted
• Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT01062425Phase 2Results posted
• Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part SarcomaCompletedNCT00942877Phase 2Results posted
• Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00795340Phase 3Results posted
• Cediranib in Combination With Lomustine Chemotherapy in Recurrent GlioblastomaCompletedNCT00777153Phase 3Results posted
• Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and BevacizumabTerminatedNCT00588900Phase 2Results posted
• Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyTerminatedNCT00527124Phase 2Results posted
• A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOXCompletedNCT00494221Phase 1/2Results posted
• Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT00475150Phase 2Results posted
• AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.CompletedNCT00454805Phase 2Results posted
• AZD2171 to Treat Prostate CancerCompletedNCT00436956Phase 2Results posted
• AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver CancerTerminatedNCT00427973Phase 2Results posted
• Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell CarcinomaCompletedNCT00423332Phase 2Results posted
• AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung CancerCompletedNCT00410904Phase 2Results posted
• Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal CancerCompletedNCT00399035Phase 3Results posted
• The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).CompletedNCT00385203Phase 2Results posted
• First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOXCompletedNCT00384176Phase 2/3Results posted
• AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the SpineTerminatedNCT00326872Phase 2Results posted
• Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By SurgeryCompletedNCT00309946Phase 2Results posted
• Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)CompletedNCT00306891Phase 2Results posted
• AZD2171 in Treating Patients With Refractory Metastatic Kidney CancerTerminatedNCT00303862Phase 2Results posted
• Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)CompletedNCT00278889Phase 2Results posted
• Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT00278343Phase 2Results posted
• AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00275028Phase 2Results posted
• Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid TumoursCompletedNCT00264004Phase 2Results posted
• AZD2171 in Treating Patients With Recurrent Small Cell Lung CancerCompletedNCT00245063Phase 2Results posted
• A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)CompletedNCT00244881Phase 2Results posted
• The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck CancerCompletedNCT00243347Phase 1Results posted
• S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By SurgeryCompletedNCT00243074Phase 2Results posted
• AZD2171 in Treating Patients With Recurrent or Stage IV MelanomaCompletedNCT00243061Phase 2Results posted
• Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By SurgeryCompletedNCT00227760Phase 2Results posted
• Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian CancerCompletedNCT07648745Phase 2
• A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical CancerActive, not recruitingNCT04487587Phase 2
• Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal MelanomaWithdrawnNCT04184518Phase 2
• Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid TumorsActive, not recruitingNCT03851614Phase 2
• Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?Status unknownNCT03570437Phase 2
• Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer PatientsStatus unknownNCT03278717Phase 3
• Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian CancerCompletedNCT03117933Phase 2
• A Study of Cediranib and Olaparib at Disease Worsening in Ovarian CancerCompletedNCT02681237Not applicable
• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...Active, not recruitingNCT02484404Phase 1/2
• A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on OlaparibCompletedNCT02340611Phase 2
• Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid MalignanciesActive, not recruitingNCT01364051Phase 1
• A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)Status unknownNCT01337401Phase 2
• Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural EffusionTerminatedNCT01262612Phase 2
• Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by SurgeryCompletedNCT01229930Phase 2
• Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY TrialTerminatedNCT01160926Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid MalignanciesCompletedNCT00981721Phase 1
• Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent GlioblastomaCompletedNCT00979862Phase 1
• Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract CancersCompletedNCT00939848Phase 2/3
• Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung CancerTerminatedNCT00937482Phase 1
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid TumoursActive, not recruitingNCT00750841Phase 1
• Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid TumoursCompletedNCT00750425Phase 1
• DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)CompletedNCT00748891Phase 1
• Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT00662506Phase 1/2
• Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid TumoursCompletedNCT00621725Phase 1
• Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer PatientsCompletedNCT00621361Phase 1
• Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer PatientsTerminatedNCT00539331Phase 1
• An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian CancerStatus unknownNCT00532194Phase 3
• A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in JapanCompletedNCT00503477Phase 1
• Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic TumorsCompletedNCT00503412Phase 1
• Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain TumourCompletedNCT00503204Phase 1
• A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid TumorsCompletedNCT00502567Phase 1
• Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AMLCompletedNCT00502385Phase 1
• Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate CancerCompletedNCT00502164Phase 1
• Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced CancerCompletedNCT00502060Phase 1
• Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver MetastasesCompletedNCT00501605Phase 1
• Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck CancerCompletedNCT00458978Phase 2
• Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic AstrocytomaCompletedNCT00458731Phase 1
• AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS TumorsCompletedNCT00326664Phase 1
• AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00321724Phase 2
• AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous LeukemiaCompletedNCT00321581Phase 1
• AZD2171 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00305656Phase 2
• Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00245154Phase 2/3
• Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedNCT00238394Phase 2

← Cediranib overview